Hilda Haynes
About
In The Last Decade
Hilda Haynes
21 papers receiving 366 citations
Peers
Comparison fields: 5 of 62
- Oncology 207
- Molecular Biology 128
- Genetics 98
- Surgery 84
- Pulmonary and Respiratory Medicine 82
Countries citing papers authored by Hilda Haynes
This map shows the geographic impact of Hilda Haynes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilda Haynes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilda Haynes more than expected).
Fields of papers citing papers by Hilda Haynes
This network shows the impact of papers produced by Hilda Haynes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilda Haynes. The network helps show where Hilda Haynes may publish in the future.
Co-authorship network of co-authors of Hilda Haynes
This figure shows the co-authorship network connecting the top 25 collaborators of Hilda Haynes. A scholar is included among the top collaborators of Hilda Haynes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilda Haynes. Hilda Haynes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 11 | |
| 4 | Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. | 109 |
| 5 | 8 | |
| 6 | Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. | 24 |
| 7 | 1 | |
| 8 | Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group. | 5 |
| 9 | 7 | |
| 10 | 17 | |
| 11 | Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. | 1 |
| 12 | Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma. | 3 |
| 13 | 16 | |
| 14 | Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo. | 26 |
| 15 | 19 | |
| 16 | 3 | |
| 17 | 9 | |
| 18 | 24 | |
| 19 | 54 | |
| 20 | 28 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.